Status:

Red

Decision Date:

July 2022

Comments

RED:

• NICE TA833 - Zanubrutinib for treating Waldenstrom’s macroglobulinaemia. NHSE commissioned. (Decision date - November 2022)
• Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned. (NICE TA expected - Late November 2023)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again